Barclays
SLN

Barclays’s Silence Therapeutics SLN Stock Holding History

Barclays’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.5K Buy
3,418
+481
+16% +$3.38K ﹤0.01% 4408
2026
Q1 		$15.5K Sell
2,937
-2,128
-42% -$11.7K ﹤0.01% 4627
2025
Q4 		$30.8K Sell
5,065
-2,071
-29% -$13.3K ﹤0.01% 4817
2025
Q3 		$37K Buy
7,136
+101
+1% +$561 ﹤0.01% 4838
2025
Q2 		$40.8K Buy
7,035
+181
+3% +$776 ﹤0.01% 4734
2025
Q1 		$19.3K Buy
6,854
+728
+12% +$3.56K ﹤0.01% 4797
2024
Q4 		$42.1K Buy
6,126
+2,793
+84% +$36K ﹤0.01% 4791
2024
Q3 		$60.6K Sell
3,333
-2,237
-40% -$41.6K ﹤0.01% 4703
2024
Q2 		$106K Hold
5,570
– – ﹤0.01% 3879
2024
Q1 		$120K Buy
+5,570
New +$121K ﹤0.01% 4366

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Barclays's SLN Position: Q2 2026 in Review

Barclays increased its Silence Therapeutics (SLN) stake by 16% in Q2 2026, buying an estimated $3.38K and bringing the position to 3,418 shares worth $37.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4408.

Barclays first reported a position in SLN in Q1 2024 and has held it in 10 quarters since. The position peaked at $120K in Q1 2024. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Barclays held 3,418 shares of Silence Therapeutics worth $37.5K as of Q2 2026.
  • Barclays bought 481 Silence Therapeutics shares in Q2 2026, an estimated $3.38K.
  • Silence Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4408 holding.
  • Barclays first reported a position in Silence Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Barclays's Silence Therapeutics position peaked at $120K in Q1 2024.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.